Form 4: Cardiff Oncology Director Gary Pace Reports Acquisition of Stock Options

Cardiff Oncology, Inc. Director Gary W. Pace has reported the acquisition of 40,565 stock options with an exercise price of $3.16, effective June 26, 2025.

Summary

• Gary W. Pace, a Director of Cardiff Oncology, Inc. (CRDF), reported the acquisition of derivative securities.
• The transaction involved 40,565 stock options, acquired on June 26, 2025.
• Each option has an exercise price of $3.16.
• The options become exercisable on June 26, 2026, and expire on June 26, 2035.
• These options underlie 40,565 shares of Common Stock.
• Following this transaction, Mr. Pace beneficially owns 187,539 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as a director's acquisition of stock options aligns their interests with shareholders, indicating confidence in the company's future performance. However, it's a routine compensation event, not a significant market-moving transaction.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• The grant of options at a $0 price indicates they were likely compensation, which is a common practice for incentivizing directors.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all industries, including the biotechnology and pharmaceutical sector where Cardiff Oncology operates. It reflects standard compensation practices for corporate directors.

Related Party Transactions

• The acquisition of stock options by Director Gary W. Pace from Cardiff Oncology, Inc. constitutes a related party transaction, as it involves a transaction between the company and one of its key management personnel.

Stakeholder Impact

• Shareholders: The grant of stock options could lead to minor future dilution if exercised, but also aligns the director's incentives with shareholder value creation.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Cardiff Oncology, CRDF, Stock Options, Insider Transaction, Form 4, Beneficial Ownership, Director Compensation, Equity Grant